BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...failures in the class included Phase III disappointments for torcetrapib from Pfizer Inc. (NYSE:PFE) and dalcetrapib...
BioCentury | May 15, 2019
Finance

Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

...areas. The decision followed discontinuation of Type II diabetes program aleglitazar and high-profile CETP inhibitor dalcetrapib...
BioCentury | Oct 13, 2017
Clinical News

End of the road for Merck's anacetrapib

...Eli Lilly and Co. (NYSE:LLY), and Pfizer Inc. (NYSE:PFE) previously discontinued development of CETP inhibitors dalcetrapib...
BioCentury | Oct 12, 2017
Clinical News

End of the road for Merck's anacetrapib

...Eli Lilly and Co. (NYSE:LLY), and Pfizer Inc. (NYSE:PFE) previously discontinued development of CETP inhibitors dalcetrapib...
...and torcetrapib, respectively, based on results of Phase III trials (see BioCentury, Jul. 7) . Allison Johnson anacetrapib dalcetrapib evacetrapib MK-0859 torcetrapib Eli...
BioCentury | Jul 7, 2017
Product Development

One small CETP for Merck

...determined to be due to off-target toxicity. The next to fall short was Roche ’s dalcetrapib...
...primary endpoint of a 15% reduction in CV events vs. placebo. Additional published data showed dalcetrapib...
...signal. REVEAL had a median follow-up of four years, whereas the follow-up for evacetrapib and dalcetrapib...
BioCentury | Jun 27, 2017
Clinical News

Merck's CETP inhibitor meets in CV outcomes study

...see BioCentury Extra, Oct. 12, 2015) . In 2012, Roche (SIX:ROG; OTCQX:RHHBY) discontinued development of dalcetrapib...
...syndrome (ACS) (see BioCentury, May 21, 2012) . DalCor Pharma U.K. Ltd. (London, U.K.) in-licensed dalcetrapib...
...the product from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) (see BioCentury, Sept. 21, 2015) . Chris Lieu AMG 899 anacetrapib dalcetrapib evacetrapib TA-8995 Amgen...
BioCentury | Apr 25, 2016
Finance

Saved by a SNP

...undisclosed other investors. This month, DalCor plans to start a 5,000-patient Phase III trial of dalcetrapib...
...transfer protein (CETP) from Roche (SIX:ROG; OTCQX:RHHBY) last year. Roche discontinued development in 2012 after dalcetrapib...
...They found patients with an AA polymorphism had a 39% decline in CV events for dalcetrapib...
BioCentury | Apr 20, 2016
Financial News

DalCor raises $100M in series B

...de solidarite FTQ, CTI Life Sciences and undisclosed investors. The company is developing dalcetrapib (formerly RG1658...
...dalcetrapib in a genetically defined subset of acute coronary syndrome patients. Roche discontinued development of dalcetrapib...
...to treat coronary heart disease (CHD). DalCor said retrospective analyses of the Roche study showed dalcetrapib...
BioCentury | Sep 21, 2015
Finance

Flower power

...were compound-specific." The failures included Phase III disappointments for torcetrapib from Pfizer Inc. (NYSE:PFE) and dalcetrapib...
BioCentury | Jul 27, 2015
Company News

Roche, DalCor deal

...Roche granted DalCor exclusive, worldwide rights to develop and commercialize dalcetrapib. DalCor plans to start a...
...May 14, 2012). The companies declined to disclose financial terms. Roche licensed ex-Japan rights to dalcetrapib...
Items per page:
1 - 10 of 44